Northwest Bioth Cmn (NWBO) News

Northwest Bioth Cmn (NWBO): $1.46

0.02 (+1.04%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add NWBO to Watchlist
Sign Up

Industry: Biotech


Ranked

of 505

in industry

Filter NWBO News Items

NWBO News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest NWBO News From Around the Web

Below are the latest news stories about Northwest Biotherapeutics Inc that investors may wish to consider to help them evaluate NWBO as an investment opportunity.

UK Manufacturing Facility & Phase III Trial Updates From Northwest Biotherapeutics (OTCQB: NWBO)

Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that an application for certification of the manufacturing facility in Sawston, UK has been submitted to the Medicines and Healthcare Products Regulatory Agency (MHRA). The Company also provided a process update on the DCVax®-L Phase III Trial.

Yahoo | May 12, 2021

Northwest Biotherapeutics Announces Development Completed for Initial Production Capacity of Sawston, UK Facility

Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that development of the initial production capacity of the Company's Sawston, UK advanced manufacturing facility has been completed and the facility is now in the final stages of preparation for an application for certification by the UK Medicines and Health Products Regulatory Authority ("MHRA").

Yahoo | March 16, 2021

Is Northwest Biotheraputics a Buy Ahead of Its Brain Tumor Vaccine Clinical Data Release?

In a short period of time, this immunotherapy biotech could either become a multi-bagger or trade near $0.

Yahoo | October 28, 2020

Northwest Biotherapeutics Announces Data Lock of Phase III Trial

Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that the database for the Phase III trial of DCVax®-L for Gliobastoma has been locked.

Yahoo | October 5, 2020


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.6555 seconds.